Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature
Acta Haematologica · 02.10.2024 · 148 (4) · 419-426
DOI: 10.1159/000541594 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Haematologica, online erschienen am 02.10.2024. Verfasst von Eyal Lebel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Treatment for relapsed/refractory AL amyloidosis (AL) is an unmet need. The safety and efficacy of belantamab mafodotin (BLM) in multiple myeloma are known, whereas in AL data are limited.
Methods
We report a multi-center cohort of AL patients receiving BLM, and review all previous data on BLM therapy in AL.
Results
Twelve patients with a median of 3 (range 2–9) prior lines of therapy were included. The overall hematological response rate (ORR) was 75% (9/12), including 5 complete responses. Six of the 10 evaluable patients had organ responses. The median event-free survivals/overall survivals were 22.3 and 28.8 months, respectively. Grade 3 toxicities were mostly infections and keratopathy, occurring in 7/12 (58%). Hematological toxicities were rare. No grade 4/5 toxicities occurred. The review of the previous series reveals BLM provides an ORR of 60–83% with similar rates of corneal toxicity.
Conclusion
BLM, being an off-the-shelf therapy, with acceptable toxicity even in frail patients, may be a valuable option in AL, with a high ORR, and a signal for durable responses and high-quality organ responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
- Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Zitieren
APA
Lebel, E., Vainstein, V., Milani, P., Palladini, G., Shragai, T., Lavi, N., Magen, H., Assayag, M., Avivi, I., & Gatt, M. E. (2024). Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica, 148(4), 419-426. https://doi.org/10.1159/000541594
Vancouver
Lebel E, Vainstein V, Milani P, Palladini G, Shragai T, Lavi N, et al. Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature. Acta Haematologica. 2024;148(4):419-426. doi:10.1159/000541594
BibTeX
@article{Lebel2024,
author = {Lebel, Eyal and Vainstein, Vladimir and Milani, Paolo and Palladini, Giovanni and Shragai, Tamir and Lavi, Noa and Magen, Hila and Assayag, Miri and Avivi, Irit and Gatt, Moshe E},
title = {Belantamab Mafodotin in Relapsed/Refractory AL Amyloidosis: Real-World Multi-Center Experience and Review of the Literature},
journal = {Acta Haematologica},
year = {2024},
volume = {148},
number = {4},
pages = {419--426},
doi = {10.1159/000541594}
}
EUVIMED